Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

NLS Pharmaceutics Presents Latest Preclinical Pipeline Data at American Society of Clinical Psychopharmacology

ZURICH, SWITZERLAND / ACCESSWIRE / April 25, 2023 / NLS Pharmaceutics Ltd. (NASDAQ: NLSP)(NASDAQ: NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, today announced it will present new and compelling preclinical data on four of its pipeline compounds at the annual meeting of the American Society of Clinical Psychopharmacology (ASCP), which is being held from May 30 to June 2, 2023, in Miami, Florida.

NLS Pharmaceutics AG, Tuesday, April 25, 2023, Press release picture

NLS Pharmaceutics' Chief Scientific Officer, Eric Konofal, MD, PhD, will present important and significant data on four compounds highlighting the company's focus on and investment in therapeutic areas of rare hypersomnia disorders and complex neurologic disorders. The NLS discovery platform currently focuses on single molecules that function through multiple mechanisms designed to target the complexity of the CNS disease state.

"We are delighted to present this compelling data on indicators such as chronic fatigue and memory associated with neurologic disorders," commented Dr. Konofal, adding "We will continue to invest in our discovery research and development programs, with the goal of adding what we believe to be promising new compounds to address the unment needs of patients with rare and complex central nervous system disorders."

Details of NLS Pharmaceutics' Research Presentations are as follows:

Title Effects of NLS-4 (Lauflumide) and modafinil in a rat model of chronic severe fatigue
Date June 1, 2023, 12:30 PM - 2:15PM
Authors Jean-Charles Bizot, Fabienne Massé, Julie Combeau, Norinne Lacerda-Queiroz, Sabrina David, Laurent Benel, George Apostol, and Eric Konofal

Title Effects of NLS-8 (Melafenoxate) on memory in a model of Alzheimer's Disease, the scopolamine-induced amnesia in the novel object recognition test in mice
Date June 1, 2023, 12:30 PM - 2:15PM
Authors Jean-Charles Bizot, Sabrina David, Fabienne Massé, Fabrice Trovero, Bruno Figadere, George Apostol, and Eric Konofal

Title Effects of NLS-11 (Benedin) on memory in the novel object recognition test in mice
Date May 31, 2023, 11:15AM - 1:00PM
Authors Jean-Charles Bizot, Sabrina David, Fabienne Massé, Fabrice Trovero, Bruno Figadere, George Apostol, and Eric Konofal

Title Effects of NLS-12 (Oxafuramine) on memory in the novel object recognition test in mice
Date 11:15AM - 1:00PM
Authors Jean-Charles Bizot, Sabrina David, Fabienne Massé, Fabrice Trovero, Bruno Figadere, George Apostol, and Eric Konofal

About NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd. (Nasdaq: NLSP) is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system, or CNS, disorders, who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.

For additional information:

Marianne Lambertson (investors & media)
NLS Pharmaceutics Ltd.
+1 239.682.8500
ml@nls-pharma.com

www.nlspharmaceutics.com

###

SOURCE: NLS Pharmaceutics AG



View source version on accesswire.com:
https://www.accesswire.com/751094/NLS-Pharmaceutics-Presents-Latest-Preclinical-Pipeline-Data-at-American-Society-of-Clinical-Psychopharmacology

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.